Related Experiment Video
Updated: Aug 15, 2025
10:44
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
9.9K
CYP2D6 pharmacogenetics and phenoconversion in personalized medicine
Noor A Nahid1, Julie A Johnson1,2
1Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, University of Florida College of Pharmacy, Gainesville, FL, USA.
Expert Opinion on Drug Metabolism & Toxicology
|January 4, 2023
Summary
Understanding CYP2D6 genetic variations and drug interactions is crucial for safe and effective medication use. Implementing CYP2D6 pharmacogenetics and phenoconversion guides precision medicine and optimizes patient outcomes.
Area of Science:
- Pharmacogenomics
- Drug Metabolism
- Clinical Pharmacology
Background:
- CYP2D6 is vital for metabolizing 20-25% of drugs, but its high polymorphism impacts drug activity.
- Drug-induced phenoconversion can alter a patient's metabolic status, affecting treatment efficacy and safety.
- Despite evidence, clinical use of CYP2D6 pharmacogenetics and phenoconversion for prescribing remains limited.
Approach:
- A literature search was conducted using PubMed and clinical studies.
- The search focused on CYP2D6 genotypes, inhibitors, drug effects, and implementation strategies.
- This review synthesizes findings on clinical importance and implementation challenges.
Key Points:
- CYP2D6 genetic variations significantly influence drug response.
- Drug interactions leading to phenoconversion can override genotypic predictions.
- Integrating pharmacogenetics and phenoconversion is essential for personalized medicine.
Conclusions:
- CYP2D6 pharmacogenetics and phenoconversion are critical for ensuring drug safety and efficacy.
- Clinical guidelines incorporating these factors can optimize drug therapy.
- Addressing implementation challenges is key to widespread clinical adoption.
Related Concept Videos
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
248
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
248
02:50Combination Therapies and Personalized Medicine
5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
01:12Analysis of Population Pharmacokinetic Data
337
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
337
01:20Chronopharmacokinetics: Time-Dependent Pharmacokinetics
173
Chronopharmacokinetics studies the temporal change in drug absorption and elimination. These changes can be cyclical or non-cyclical. Cyclical changes occur over a regular interval, while non-cyclical changes occur over a longer, irregular period.
Time-dependent pharmacokinetics refers to non-cyclical changes in drug rate processes over a period of time. It can lead to nonlinear pharmacokinetics, where the relationship between drug concentration and time is not proportional. Non-cyclical...
Time-dependent pharmacokinetics refers to non-cyclical changes in drug rate processes over a period of time. It can lead to nonlinear pharmacokinetics, where the relationship between drug concentration and time is not proportional. Non-cyclical...
173
01:27Nonlinear Pharmacokinetics: Role of Transporters
81
A drug's nonlinear kinetics can be influenced by a diverse range of transporter proteins that serve as crucial players in drug distribution. These transporters, found within cells, can enhance or reduce local drug concentrations by facilitating the influx or efflux of drugs. For instance, the expression of xenobiotic transporters can be influenced by factors such as age and gender, potentially impacting the linearity of drug response.
Polymorphisms occurring in drug transporters can alter...
Polymorphisms occurring in drug transporters can alter...
81
01:16Drug Biotransformation: Overview
2.5K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.5K